228 related articles for article (PubMed ID: 24439786)
1. Toremifene for breast cancer: a review of 20 years of data.
Vogel CL; Johnston MA; Capers C; Braccia D
Clin Breast Cancer; 2014 Feb; 14(1):1-9. PubMed ID: 24439786
[TBL] [Abstract][Full Text] [Related]
2. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
Baumann CK; Castiglione-Gertsch M
Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
[TBL] [Abstract][Full Text] [Related]
3. Clinical usefulness of high-dose toremifene in patients relapsed on treatment with an aromatase inhibitor.
Yamamoto Y; Masuda N; Ohtake T; Yamashita H; Saji S; Kimijima I; Kasahara Y; Ishikawa T; Sawaki M; Hozumi Y; Iwase H
Breast Cancer; 2010 Oct; 17(4):254-60. PubMed ID: 19685269
[TBL] [Abstract][Full Text] [Related]
4. Crossover trial for lipid abnormality in postmenopausal breast cancer patients during selective estrogen receptor modulators (SERMs) administrations.
Kusama M; Kaise H; Nakayama S; Ota D; Misaka T; Aoki T
Breast Cancer Res Treat; 2004 Nov; 88(1):9-16. PubMed ID: 15538041
[TBL] [Abstract][Full Text] [Related]
5. Toremifene: an evaluation of its safety profile.
Harvey HA; Kimura M; Hajba A
Breast; 2006 Apr; 15(2):142-57. PubMed ID: 16289904
[TBL] [Abstract][Full Text] [Related]
6. Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies.
Johnston SR
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4376s-4387s; discussion 4411s-4412s. PubMed ID: 11916228
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. Finnish Breast Cancer Group.
Holli K; Valavaara R; Blanco G; Kataja V; Hietanen P; Flander M; Pukkala E; Joensuu H
J Clin Oncol; 2000 Oct; 18(20):3487-94. PubMed ID: 11032589
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Postmenopausal Breast Cancer with Selective Estrogen Receptor Modulators (SERMs).
Lewis-Wambi JS; Jordan VC
Breast Dis; 2005-2006; 24():93-105. PubMed ID: 16917142
[TBL] [Abstract][Full Text] [Related]
9. Hormonal therapy for postmenopausal breast cancer: the science of sequencing.
Miller WR; Bartlett JM; Canney P; Verrill M
Breast Cancer Res Treat; 2007 Jun; 103(2):149-60. PubMed ID: 17039263
[TBL] [Abstract][Full Text] [Related]
10. Selecting adjuvant endocrine therapy for breast cancer.
Eneman JD; Wood ME; Muss HB
Oncology (Williston Park); 2004 Dec; 18(14):1733-44, discussion 1744-5, 1748, 1751-4. PubMed ID: 15700624
[TBL] [Abstract][Full Text] [Related]
11. Effects of toremifene and tamoxifen on lipid profiles in post-menopausal patients with early breast cancer: interim results from a Japanese phase III trial.
Tominaga T; Kimijima I; Kimura M; Takatsuka Y; Takashima S; Nomura Y; Kasumi F; Yamaguchi A; Masuda N; Noguchi S; Eshima N
Jpn J Clin Oncol; 2010 Jul; 40(7):627-33. PubMed ID: 20382637
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of high-dose toremifene therapy in postmenopausal patients with metastatic breast cancer resistant to aromatase inhibitors:a retrospective, single-institution study.
Ishizuna K; Ninomiya J; Ogawa T; Tsuji E; Kojima M; Kawashima M; Nozaki M; Yamagishi H; Ueda Y; Oya M
Gan To Kagaku Ryoho; 2014 Aug; 41(8):965-70. PubMed ID: 25132027
[TBL] [Abstract][Full Text] [Related]
13. Uterine changes during tamoxifen, toremifene, and other therapy for breast cancer: evaluation with magnetic resonance imaging.
Ochi J; Hayakawa K; Moriguchi Y; Urata Y; Yamamoto A; Kawai K
Jpn J Radiol; 2010 Jul; 28(6):430-6. PubMed ID: 20661693
[TBL] [Abstract][Full Text] [Related]
14. Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer.
Lewis JD; Chagpar AB; Shaughnessy EA; Nurko J; McMasters K; Edwards MJ
Cancer; 2010 May; 116(10):2307-15. PubMed ID: 20209619
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic evaluation of toremifene and its clinical implications for the treatment of osteoporosis.
Gennari L; Merlotti D; Stolakis K; Nuti R
Expert Opin Drug Metab Toxicol; 2012 Apr; 8(4):505-13. PubMed ID: 22356442
[TBL] [Abstract][Full Text] [Related]
16. Phase II clinical trial of high-dose toremifene as primary hormone therapy in aromatase inhibitor-resistant breast cancer.
Ogata H; Okamoto Y; Arima Y; Fukushima H; Takeyama H; Yamashita A; Kinoshita M; Suzuki N; Sawada T; Koshida Y; Matsui A; Tachibana A; Nakayama H; Oishi Y; Nogi H; Uchida K
Gan To Kagaku Ryoho; 2013 Jun; 40(6):749-53. PubMed ID: 23863651
[TBL] [Abstract][Full Text] [Related]
17. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
Gradishar WJ
Oncology; 2005; 69(1):1-9. PubMed ID: 16088229
[TBL] [Abstract][Full Text] [Related]
18. Vascular effects of aromatase inhibitors: data from clinical trials.
Howell A; Cuzick J
J Steroid Biochem Mol Biol; 2005 May; 95(1-5):143-9. PubMed ID: 15936188
[TBL] [Abstract][Full Text] [Related]
19. Low-grade endometrial stromal sarcoma developing in a postmenopausal woman under toremifene treatment for breast cancer.
Kashiyama T; Oda K; Kawana K; Arimoto T; Kanetaka Y; Takazawa Y; Maeda D; Nakagawa S; Yano T; Kozuma S
J Obstet Gynaecol Res; 2013 Jan; 39(1):424-9. PubMed ID: 22690656
[TBL] [Abstract][Full Text] [Related]
20. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
Berry J
Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
